News

Video

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

Author(s):

Caron Jacobson, MD,Miguel-Angel Perales, MD

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
Related Content
Leo I. Gordon, MD
December 2nd 2024

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Elias Jabbour, MD
November 26th 2024

Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing

FDA
November 25th 2024

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers